Biosafety law is coming out, and pharmaceutical enterprises with strong innovation and R & D capability have been concerned for a long time

[pharmaceutical network industry trends] "from the perspective of protecting people's health, safeguarding national security and maintaining the long-term stability of the country, we should integrate biosafety into the national security system, and promote the introduction of biosafety law as soon as possible." The biosafety law is about to come out, and the subdivision plate that conforms to the development trend of the policy is also concerned by people It is recommended to pay attention to enterprises with strong innovation and R & D capability for a long time, such as Hengrui pharmaceutical, Beida pharmaceutical, etc Hengrui pharmaceutical is a leading domestic pharmaceutical company The industry believes that the company's innovative pharmaceutical sector has entered the harvest period, and the rich pipeline under research will provide a solid impetus for the company's long-term development The company is successfully transforming into a domestic "innovation" leader At present, the company has 6 innovative drug products, including PD-1 and pyrrolidine, which have formed a good situation of 1-2 innovative drugs listed every year In 2019, the company's innovative drug revenue contribution is expected to reach 5 billion yuan, accounting for ~ 21% of the revenue, achieving rapid growth compared with 2018 ~ 2.5 billion yuan (accounting for ~ 14%), and the rapid release of innovative drugs has become a new driving force for the company's growth Independent research and development, strategic cooperation and marketing are gradually becoming the three carriages driving better and faster development of Beida pharmaceutical industry According to the data of the third quarter report newly disclosed by Beida pharmaceutical, from January to September 2019, the company achieved an operating revenue of 1.24 billion yuan, a year-on-year increase of 34.05%; a net profit attributable to the parent company of 199 million yuan, a year-on-year increase of 34.37%; and a non net profit deduction of 181 million yuan, a year-on-year increase of 42.87% Today, Beida pharmaceutical industry has grown into a high-tech pharmaceutical enterprise with independent intellectual property rights innovation drug research and development as the core, integrating research and development, production and marketing According to the data, at present, the company has nearly 30 new drugs under research and 4 technical standards, among which the standard of exetane hydrochloride API and tablet has become the national standard, and has won the national "major new drug creation" major science and technology special projects for many times According to the industry, with the continuous development of China's economic level, people pay more and more attention to health, and all sectors of society invest more and more in medical care In 2018, the growth rate of per capita medical and health care consumption expenditure in China was as high as 16%, significantly higher than the growth rate of overall consumption expenditure, which are inexhaustible driving forces for the long-term development of the pharmaceutical industry In this regard, the industry said that it is very optimistic about the development prospects of innovative drugs in China China's pharmaceutical industry has entered the stage of transformation and upgrading In recent years, a large number of generic drugs with independent intellectual property rights have emerged, and even a number of new drugs have been approved or under research "China has outstanding talent advantages in the biomedical industry, and policy orientation also encourages innovation In the long run, we will see more and more innovative drugs made in China." With the strengthening of policy inclination and the substantial increase of approval speed, China's innovative drug market has ushered in new market opportunities According to relevant data, in 2018, the size of China's generic drug market reached US $103 billion, accounting for 44.5% of China's total pharmaceutical market It is estimated that by 2023, China's generic drug market will increase to US $137.7 billion, with a compound annual growth rate of 6% from 2018 to 2023 In the next five years, under the policy of encouraging the development of innovative drugs, its market size is expected to increase at a compound annual growth rate of 7.5% over the same period to US $184.4 billion in 2023 Compared with the low price competition among generic drugs, it is an inevitable choice for generic companies to develop incremental varieties, including innovative drugs Therefore, domestic pharmaceutical companies pay more and more attention to the research and development of innovative drugs With the coming of biosafety law, innovative pharmaceutical companies have attracted more and more attention